Status:

COMPLETED

Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients

Lead Sponsor:

Pfizer

Conditions:

Tuberculosis

Non-tuberculous Mycobacterial Diseases (Including MAC Disease)

Eligibility:

All Genders

Brief Summary

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in thi...

Detailed Description

All the patients whom an investigator prescribes the first Mycobutin® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into t...

Eligibility Criteria

Inclusion

  • Patients need to be administered Mycobutin® in order to be enrolled in the surveillance.

Exclusion

  • Patients not administered Mycobutin®.

Key Trial Info

Start Date :

November 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 1 2016

Estimated Enrollment :

628 Patients enrolled

Trial Details

Trial ID

NCT00810407

Start Date

November 1 2008

End Date

July 1 2016

Last Update

March 7 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.